For this, VSV-GP-specific CD8+ T cell responses were monitored using the identified VSV-GP BALB/c epitopes in mice engrafted with the widely used colon carcinoma cell line CT26.CL25 and treated with 108 TCID50 VSV-GP either i.v. or i.t. Seven days post OV treatment, spleens and tumors were harvested; splenocytes and tumor-infiltrating lymphocytes (TILs) were stimulated ex vivo with the 11 immunogenic H2-Kd-, H2-Dd-, and H2-Ld-presented peptides and were analyzed for their ability to induce intracellular IFN-γ production in T cells (Figure 5A). The gene discussed is CD8A; the disease is colon carcinoma.